Aardvark Therapeutics (AARD) News Today $8.30 -0.19 (-2.24%) As of 08/29/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock AARD Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Aardvark Therapeutics (NASDAQ:AARD) Price Target Cut to $25.00 by Analysts at Bank of AmericaAugust 30 at 12:06 PM | marketbeat.comAardvark Therapeutics (NASDAQ:AARD) Price Target Lowered to $25.00 at Bank of AmericaAugust 29 at 3:15 AM | americanbankingnews.comAardvark Therapeutics to Present at Upcoming Investor Conferences in SeptemberAugust 27, 2025 | globenewswire.comAardvark Therapeutics Advances Clinical Trials and FinancialsAugust 26, 2025 | tipranks.comAnalysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) Price Target at $32.80August 24, 2025 | americanbankingnews.comHC Wainwright Has Pessimistic Outlook of AARD Q3 EarningsAugust 22, 2025 | marketbeat.comHC Wainwright Brokers Reduce Earnings Estimates for AARDAugust 22, 2025 | americanbankingnews.comAardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Buy" by BrokeragesAugust 21, 2025 | marketbeat.comCantor Fitzgerald Has Negative View of AARD FY2025 EarningsAugust 19, 2025 | marketbeat.comAardvark Therapeutics (NASDAQ:AARD) Announces Quarterly Earnings ResultsAugust 16, 2025 | marketbeat.comRoyal Bank Of Canada Lowers Aardvark Therapeutics (NASDAQ:AARD) Price Target to $19.00August 16, 2025 | marketbeat.comAardvark Therapeutics price target lowered to $19 from $20 at RBC CapitalAugust 14, 2025 | msn.comAardvark Therapeutics reports Q2 EPS (66c), consensus (60c)August 13, 2025 | msn.comAardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business UpdatesAugust 13, 2025 | globenewswire.comAardvark Therapeutics Reveals Promising Preclinical Data for ARD-201August 12, 2025 | msn.comAardvark Therapeutics announces preclinical data on ARD-201August 12, 2025 | msn.comRetail investors among Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) largest stockholders and were hit after last week's 11% price dropAugust 12, 2025 | finance.yahoo.comAardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA TherapyAugust 12, 2025 | globenewswire.comAardvark Therapeutics, Inc.'s (NASDAQ:AARD) Lock-Up Period Set To Expire on August 12thAugust 5, 2025 | marketbeat.com3,917,299 Shares in Aardvark Therapeutics, Inc. (NASDAQ:AARD) Purchased by Decheng Capital LLCJuly 30, 2025 | marketbeat.comAardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Buy" from BrokeragesJuly 26, 2025 | marketbeat.comAardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)July 18, 2025 | globenewswire.comAARD - Aardvark Therapeutics Inc Chart - MorningstarJuly 10, 2025 | morningstar.comMAardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI DistressJuly 3, 2025 | finance.yahoo.comTrending Stocks By Analyst’s for this Week - The Globe and MailJuly 2, 2025 | theglobeandmail.comQ2 Earnings Estimate for AARD Issued By HC WainwrightJuly 2, 2025 | marketbeat.comLatest Aardvark Therapeutics Stock News | NASDAQ:AARD - BenzingaJuly 1, 2025 | benzinga.comHC Wainwright & Co. Initiates Coverage of Aardvark Therapeutics (AARD) with Buy RecommendationJune 30, 2025 | msn.comAardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Rating of "Buy" from BrokeragesJune 30, 2025 | marketbeat.comAardvark Therapeutics (NASDAQ:AARD) Coverage Initiated by Analysts at HC WainwrightJune 30, 2025 | marketbeat.comAARD - Aardvark Therapeutics Inc Executives - MorningstarJune 24, 2025 | morningstar.comMAardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope ConferenceJune 24, 2025 | globenewswire.comA revolutionary drug for extreme hunger offers clues to obesity’s complexityJune 20, 2025 | msn.comBreakthrough drug helps rare obesity condition, but other research uncertain amid cutsJune 17, 2025 | cbsnews.comBreakthrough drug helps rare obesity condition. Other research uncertain amid cuts.June 16, 2025 | msn.comWall Street Zen Downgrades Aardvark Therapeutics (NASDAQ:AARD) to SellJune 14, 2025 | marketbeat.comInvestigational Long-Acting Drug Safe in Phenotypic MASHJune 13, 2025 | msn.comCantor Fitzgerald Forecasts AARD FY2026 EarningsJune 10, 2025 | marketbeat.comAardvark Therapeutics (NASDAQ:AARD) Raised to "Hold" at Wall Street ZenJune 6, 2025 | marketbeat.comBiotech IPO Slump Seen Dragging Into 2026 as Returns DisappointMay 27, 2025 | msn.comEquities Analysts Set Expectations for AARD FY2025 EarningsMay 21, 2025 | marketbeat.comAardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal FunctionsMay 19, 2025 | globenewswire.comCantor Fitzgerald Remains a Buy on Septerna, Inc. (SEPN)May 18, 2025 | theglobeandmail.comAardvark Therapeutics Reports Phase 3 HERO Trial Progress for ARD-101 in Prader-Willi Syndrome and Financial Results for Q1 2025May 16, 2025 | nasdaq.comAardvark Therapeutics, Inc.: Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 15, 2025 | finanznachrichten.deAardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 14, 2025 | globenewswire.comAardvark Therapeutics to Present at Upcoming Investor Conferences in MayMay 7, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Organon (OGN) and Cardinal Health (CAH)May 7, 2025 | theglobeandmail.comAardvark Therapeutics (NASDAQ:AARD) Trading Up 7.6% - What's Next?April 25, 2025 | marketbeat.comAardvark Therapeutics, Inc. Common Stock (AARD)April 18, 2025 | finance.yahoo.com Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AARD Media Mentions By Week AARD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AARD News Sentiment▼-0.061.09▲Average Medical News Sentiment AARD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AARD Articles This Week▼63▲AARD Articles Average Week Get the Latest News and Ratings for AARD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aardvark Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies OCS News ABUS News SNDL News GHRS News TBPH News PROK News VIR News MNMD News KURA News KALV News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AARD) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AARD Stock Alerts